Lumensia Sensors, S.L. participates in the following European R&D projects:

Proyecto ALMOND


Nº Proyecto: INNCAD00/18/025

Programa: Consolidación de la cadena de valor empresarial

Título: AlLergen Management phOtoNics Device

LUMENSIA SENSORS was funded in 2013 with the aim of developing biosensing devices based on its Photonics Integrated Circuits property technology. Where application fields are Health, Food Safety, Environment and Defence.


LUMENSIA SENSORS has already developed a sensing platform based on its photonics technology for the detection of allergens in food matrixes. That technology allows a fast detection of allergens (20 min) with highly impressive features as multianalyte possibility (up until 6 allergens simultaneously), label-free, accuracy, specificity, high sensitivity (Limit of detection lower that ppm) and low cost (disposable cartridge manufacturing costs below 10€).


With the proposal INNCAD00/18/025, LUMENSIA aims to reach maturity of the technology and to be ready for product certification phase and subsequent commercialization during 2019. Tasks to be carried out from August to December_2018, are focused towards the improvements in some critical parts of the already developed sensing platform in order to overtake current version functional limitations. With this objective, there are necessary new specific developments not only in hardware but also in software for signal processing.


This project is part of a much bigger proposal that was awarded by the European Commission with a Seal of Excellence in the call [H2020-EIC-SMEInst-2018-2020 (H2020-SMEInst-2018-2020-2)] in May 2018. However, finally it was not a founded project.


LUMENSIA will commercialize a product in two different market segments: On the one hand, meat sector companies that are large enough to have their own laboratories. On the other hand, laboratories offering analytical services to another companies. Very important companies have shown they support to LUMENSIA project as well as their interest to this technology. Furthermore, LUMENSIA has guaranteed the value chain by signing contracts with critical suppliers in order to guarantee the industrial production.



Nº Project: 7711649



The increased population density in modern animal production systems has made them vulnerable to various transboundary infectious agents that threaten productivity of the meat industry extending the effects of diseases far beyond animal sickness and mortality.


Therefore, early diagnosis and establishment of reliable countermeasures to infectious disease outbreaks is essential to limit severe biophysical and socio-economic consequences.

Thus, the need for the development of mobile diagnostic units has been recently recognized. Reliable and simple diagnostic testing directly on site would enable rapid local decision making which is crucial to prevent further spreading of the disease.

SWINOSTICS addresses these challenges and needs, by developing a novel field diagnostic device, based on advanced, proven, bio-sensing and photonics technologies to tackle emerging and endemic viruses (ASFV, PRRSV, H1N1, PPV, PCV2 and CSF) causing epidemics in swine farms in Europe that lead to relevant economic damages. The diagnostic device will allow immediate threat assessment at the farm level, with the analytical quality of commercial and institutional laboratories. The device will be portable and will provide results in 10 minutes for 5 samples simultaneously, making it highly suitable for use in the field.

Project PLATON


Nº Project: IDI-20160244



The main objective of the project is the development and manufacturing of a biosensing device based on photonics technology and the implementation up until pre-commercial level on applications for biologic sensing control (allergen and pathogenic analytes) for the improvement of the processes within food sector.


A more concrete project objective is that the developed application will allow to get the same performances than current sensing and control methods in terms of sensibility, improving current sensing limitations. PLATON biosensing device will allow having results within minutes with high specificity and sensibility with multitarget capacity. The developed device will also show other interesting features like no sample preparation required, label-free and cost effective…


Proposed ring resonators based technology is an outcome from R+D implemented projects, that has been tested at laboratory level (TRL4). The objective is increase this TRL up until TRL6-7 (pre-comercial level) by the redesign of part of that technology and also concreting some other exclusive aspects of the application.


PLATON project will be concreted on an application for allergen and pathogen sensing on industrial lines.


The created device is based on two main components: a BASE STATION and a DISPOSABLE CARTRIDGE. This approach tries to simplify the analysis method and to reduce the cost of the tests.

On the other hand, due to the strong relationship between LUMENSIA and NTC-UPV, there have been achieved huge advances on the development of new sensing technologies based on SPR On-Chip. That new technology could also be introduced on industrial applications, thus guaranteeing the next technologic developments of LUMENSIA.



Nº Project: 688448


Drug hypersensitivity to antibiotics, mainly Beta-lactams (BLCs) affects more than 2.5 million European citizens. Moreover, preventable adverse drug reactions are estimated in additional hospitalization costs of 1750-4500 €/patient. Currently, the allergy diagnosis is mainly based on the information given by invasive, single, and risky in vivo assays. In daily practice, few in vitro diagnostic methods are available and only used at the tertiary health services. These tests also lack sensitivity (>0.35 kUA/L) and selectivity (<98%), resulting in an inaccurate diagnosis, analyze few drugs allergens (5), are time consuming (60-180 min), and expensive (30 €/allergen).

COBIOPHAD aims the development of an innovative in vitro diagnostic (IVD) device for diagnosis of IgE-mediated drug allergies by building an integrated biophotonic system based on compact disc technology. For that, key enabling technologies will be integrated in order to achieve high sensitive (<0.1 kUA/L), selective (>98%), multiplexed (10 BLCs), rapid (30 min), and low-cost (2.4 €/allergen) drug allergy test.


The solution involves an advanced approach to the diagnosis and management of drug allergy with the aim to ameliorate patient safety. The consortium comprises multidisciplinary knowledge on optics, electronics, advanced materials, biotechnology, smart microstructures, microfluidics, surface/organic chemistry, allergy, manufacturing systems, and telecom networking. Also, the key industrial actors, present in the consortium, will contribute to the manufacturing and placing the product on the IVD market